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Abstract 17 
Many studies have quantified pharmaceuticals in the environment, few however, 18 
have incorporated detailed temporal and spatial variability due to associated costs in 19 
terms of time and materials. Here, we target 33 physico-chemically diverse 20 
pharmaceuticals in a spatiotemporal exposure study into the occurrence of 21 
pharmaceuticals in the wastewater system and the Rivers Ouse and Foss (two diverse 22 
river systems) in the city of York, UK. Removal rates in two of the WWTPs sampled (a 23 
carbon activated sludge (CAS) and trickling filter plant) ranged from not eliminated 24 
(carbamazepine) to >99% (paracetamol). Data comparisons indicate that 25 
pharmaceutical exposures in river systems are highly variable regionally, in part due to 26 
variability in prescribing practices, hydrology, wastewater management, and urbanisation 27 
and that select annual median pharmaceutical concentrations observed in this study 28 
were higher than those previously observed in the European Union and Asia thus far. 29 
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Significant spatial variability was found between all sites in both river systems, while 30 
seasonal variability was significant for 86% and 50% of compounds in the River Foss 31 
and Ouse, respectively. Seasonal variations in flow, in-stream attenuation, usage and 32 
septic effluent releases are suspected drivers behind some of the observed temporal 33 
exposure variability. When the data were used to evaluate a simple environmental 34 
exposure model for pharmaceuticals, mean ratios of predicted environmental 35 
concentrations (PECs), obtained using the model, to measured environmental 36 
concentrations (MECs) were 0.51 and 0.04 for the River Foss and River Ouse, 37 
respectively. Such PEC/MEC ratios indicate that the model underestimates actual 38 
concentrations in both river systems, but to a much greater extent in the larger River 39 
Ouse. 40 
Keywords: LC-MS/MS; surface water; wastewater; seasonal; exposure; predicted 41 
environmental concentration 42 
 43 
1.0 Introduction 44 
Determining pharmaceutical exposures in environmental matrices has become a 45 
substantial area of research since the 1990s (Daughton, 2016). The presence of 46 
pharmaceuticals in freshwater systems has now been documented globally, with 47 
research especially focused in Europe and North America (aus der Beek et al., 2016). 48 
Pharmaceuticals primarily enter the environment through patient use when an 49 
unmetabolised fraction is excreted and subsequently passes through wastewater 50 
treatment plants (WWTPs), which are typically not designed to remove such organic 51 
contaminants (Luo et al., 2014). Consequently, WWTPs are significant sources of 52 
pharmaceuticals to the environment (Lindholm-Lehto et al., 2016). A recent study of 53 
United Kingdom (UK) WWTPs estimated that 13% of effluent discharges could pose 54 
risks to the receiving environment regarding pharmaceutical exposures (Comber et al., 55 
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2018).  Removal rates are highly variable between treatment types (Kasprzyk-Hordern et 56 
al., 2009; Luo et al., 2014), seasons (Golovko et al., 2014), and even within treatment 57 
plants themselves (Verlicchi et al., 2012).  Moreover, removal rates have only been 58 
estimated for a small fraction of the total number of pharmaceuticals in use (Boxall et al., 59 
2014) and only a few studies have reported WWTP removals in the UK specifically 60 
(Comber et al., 2018; Kasprzyk-Hordern et al., 2009, 2008). WWTP removal rates are 61 
valuable parameters, and their inclusion in occurrence modelling substantially improves 62 
the accuracy of pharmaceutical exposure predictions (Burns et al., 2017; Verlicchi et al., 63 
2014).  64 
The potential for, and extent of, effects posed by pharmaceutical exposure to non-65 
target organisms, such as fish or invertebrates, is largely unknown (Vasquez et al., 66 
2014). However, there is mounting evidence that select pharmaceuticals are having 67 
deleterious effects at environmentally relevant (i.e. real-world) concentrations. Examples 68 
of documented effects at environmentally relevant concentrations include 69 
antidepressants causing behavioural changes in fish (fluoxetine) (Mccallum et al., 2017), 70 
disruption during early development (venlafaxine) (Thompson et al., 2017), the 71 
equivalent of human side effects from exposure to the anti-diabetic drug metformin 72 
(Niemuth et al., 2015) or the feminization of wild fish populations downstream of a 73 
pharmaceutical manufacturing facility in France (Sanchez et al., 2011). It is therefore 74 
important to characterise the source and fate of pharmaceuticals in the aquatic 75 
environment to aid in risk assessment as approaches evaluating potential adverse effect 76 
concentrations emerge. 77 
To adequately characterise the fate of pharmaceuticals in the environment, robust 78 
monitoring campaigns which include seasonal or year-long sampling covering a range of 79 
compounds at a reasonable spatial resolution are required. However, only a small 80 
number of spatiotemporal exposure studies have been performed that meet these 81 
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criteria (Baker and Kasprzyk-Hordern, 2013; Daneshvar et al., 2010; Kasprzyk-Hordern 82 
et al., 2008; Paíga et al., 2016). These exposure studies are extremely valuable as they 83 
provide detailed information which can be related back to the myriad of factors (many 84 
varying both seasonally and temporally) that influence environmental concentrations of 85 
pharmaceuticals including hydrology (Kasprzyk-Hordern et al., 2008), WWTP removal 86 
efficiency (Silva et al., 2014), pharmaceutical usage (Sun et al., 2014), and in-stream 87 
removal processes (e.g. biodegradation and sorption to sediment) (Daneshvar et al., 88 
2010; Camacho-Munoz et al., 2010; Moreno-González et al., 2014). In combination, the 89 
impact of these processes on pharmaceutical exposure and fate is largely unknown but, 90 
if better defined, could improve exposure prediction approaches and offer greater 91 
confidence, in terms of exposure, when evaluating risks that pharmaceuticals may pose 92 
to the environment.   93 
Recently, a handful of aqueous rapid pharmaceutical determination high-94 
performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) 95 
methods have been developed that achieve comparable limits of detection (LODs) to 96 
those including sample pre-concentration or clean-up (Anumol et al., 2015; Boix et al., 97 
2015; Campos-Mãnas et al., 2017; Furlong et al., 2014; Oliveira et al., 2015). Such 98 
methods involve utilising larger than normal injection volumes (~100 µL) to increase the 99 
likelihood of detection (Petrie et al., 2016). Removal of the extraction step reduces 100 
sample preparation time and can increase the number of samples that can be processed 101 
(highly beneficial to large spatiotemporal exposure campaigns). A significant analytical 102 
problem arising during pharmaceutical quantification is matrix effects (typically mass 103 
spectrometric ionisation enhancement or suppression). The presence of background 104 
interferences in “dirty” matrices (e.g. streams, WWTP effluent, etc.) can co-elute with 105 
target analytes and impair quantification past the point of suitability (Petrović et al., 106 
2005). Several approaches have been attempted to reduce matrix effects including 107 
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sample pre-concentration and clean-up to help isolate target pharmaceuticals (Van De 108 
Steene et al., 2006). Such pre-concentration, however, is difficult to optimise, time 109 
consuming, costly, and may also concentrate interfering analytes, thus unintentionally 110 
increasing matrix effects (Yu et al., 2012). Matrix interferences have been reported to be 111 
comparatively lower for rapid determination methods than more costly and laborious 112 
sample pre-concentration/clean-up methods (Anumol et al., 2015).  113 
In this study, which was performed in the frame of the Innovative Medicines 114 
Initiative iPiE project on intelligent assessment of pharmaceuticals in the environment, 115 
we validate and apply a rapid determination aqueous HPLC-MS/MS method for the 116 
quantification of 33 physico-chemically diverse pharmaceuticals to a year-long surface-117 
water exposure campaign. Monitoring was conducted during 2016 at 11 sites along the 118 
urbanised and larger River Ouse and smaller, more rural River Foss which converge 119 
within the city of York, UK (Figure 1). The monthly sampling design provided good 120 
temporal resolution while unparalleled spatial resolution was achieved in the two 121 
contrasting river systems. In addition, influent and effluent samples from two of the 122 
WWTPs that serve the city were collected when possible and removal efficiencies 123 
estimated. Predicted exposure concentrations (PECs) were calculated for both rivers 124 
using a simple model and the model was then evaluated against annually averaged 125 
measured environmental concentrations (MECs) calculated from the monthly sampling 126 
data. 127 
2.0 Methods 128 
2.1 Study area and sample collection 129 
2.1.1 Study Compounds 130 
Study compounds were selected based on those previously detected in the York 131 
river system during an initial scoping study in which 95 pharmaceutical and degradation 132 
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products were surveyed (Burns et al., 2017). From these results, 32 pharmaceuticals 133 
were selected due to either their known or expected presence. An additional compound, 134 
gabapentin, was also included in the study due to its high usage, resistance to 135 
environmental degradation, and ecotoxic potential (Herrmann et al., 2015).  136 
2.1.2 Study Area 137 
The River Ouse and River Foss were chosen for the study, as they flow through 138 
the city of York, UK, and converge downstream of the city centre (Figure 1). The two 139 
rivers represent differing levels of urbanisation and size. To minimise potential variability, 140 
grab water samples were collected from the network of 11 sampling sites in the same 141 
order and on approximately the same day and time each month from January to 142 
December 2016. Site locations were strategically chosen based on their ease of access 143 
and position in relation to WWTP outfalls. Both rivers were sampled with sufficient 144 
spatial resolution to build concentration profiles and increase the probability of detecting 145 
transient pharmaceuticals in the absence of composite sampling techniques. Three 146 
WWTPs serve the city within the sampling network (Figure 1). WWTP A is a trickling 147 
filter plant and serves a population of 18 600, WWTP B is a conventional activated 148 
sludge (CAS) facility serving a population of 27 900, while WWTP C is a surplus 149 
activated sludge (SAS) plant serving a population of 180 500. Sampling site and WWTP 150 
characteristics along with dates of sampling are detailed in Supplemental Material, 151 
Tables S1 and S2.  152 
2.1.3 Sample Collection 153 
All samples collected were subject to the same sampling protocol. At each site, 154 
three 1-L field replicates were collected from the centroid of flow (when possible); 155 
sampling sites had been previously determined to be well-mixed, therefore sampling in a 156 
single location was deemed appropriate (Supplemental Material, Figure S1). For each 157 
field replicate, a 10-mL aliquot was drawn into a 24-mL disposable syringe and filtered 158 
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through a primed 0.7-µm glass-fibre filter (GF/F) (Whatman Inc.) into an amber glass vial 159 
and immediately frozen in the field using dry ice. To demonstrate that field filtration and 160 
collection did not contaminate samples, three field blanks per sampling visit were 161 
collected. HPLC-grade water was brought to the field, filtered and prepared identically to 162 
field samples. Samples were then returned to the laboratory and stored at -18°C until 163 
analysis which occurred within seven days. The concentration reported for each sample 164 
per site is the median of the three field replicates collected. The filtering of samples in 165 
the field is beneficial as it removes particulates which can extend HPLC column life, 166 
reduce instrument maintenance, as well as remove bacteria associated with particulates 167 
that could facilitate analyte degradation. There is a formal possibility that analytes could 168 
be retained on the filter; however pharmaceutical filtration studies including 26 169 
compounds (acids, bases and amphoteres) ranging in hydrophobicity (logKow -2.3 to 170 
6.3) suggest these losses will be insignificant (<5%) (Mompelat et al., 2013), thus an 171 
assessment of filter losses has not been repeated here.  172 
2.2 High performance liquid chromatography-tandem mass spectrometry 173 
A Thermo Scientific™ TSQ Endura MS operating in multiple reaction monitoring 174 
mode interfaced with an EASY-Max NG™ heated electrospray source operating in 175 
positive mode was used for pharmaceutical detection. Two transitions were monitored 176 
for each analyte and the m/z and collision energy optimised using the Thermo™ Tune 177 
2.0 software, summarised in Supplemental Material, Table S3. Chromatographic 178 
separation was achieved with a Dionex Ultimate 3000 HPLC (Thermo Scientific™) 179 
equipped with a 100-µL sample injection loop and autosampler maintained at 4°C. 180 
Mobile phase A consisted of HPLC-grade water amended with 12-mL of 1 M formic acid 181 
and 10-mL of 1 M ammonium hydroxide for a total volume of 1-L, and mobile phase B 182 
was 100% methanol (Furlong et al., 2014). The chromatographic conditions and 183 
program are reported in the Supplemental Material Table S4. 184 
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 Internal standard (IS) calibration was used to quantify the pharmaceuticals in the 185 
method described. For reasons of expense and availability, not all pharmaceuticals had 186 
a corresponding isotopically labelled internal standard (ILIS) (Supplemental Material, 187 
Table S3). In these cases, atrazine-d5 was used and has been previously determined 188 
suitable for this role (Furlong et al., 2014). Samples were fully thawed and a 995-µL 189 
aliquot pipetted into a 1.5-mL LC vial and a 5-µL spike of IS solution (80 ng/L) added. 190 
Samples were immediately analysed after preparation. Peak detection criteria were in 191 
accordance with Commission Decision (2002/657/EC). Due to analytical complications, 192 
fexofenadine could not be quantified in the April surface-water samples. Further details 193 
of peak qualification and quantitation are provided in the Supplementary Material. 194 
The use of ILIS is a good strategy to compensate for matrix effects (Stüber and 195 
Reemtsma, 2004). This is not a perfect solution as matrix effects can still influence 196 
quantification, possibly due to a slight difference in retention time (tR) between the ILIS 197 
and target analyte resulting in differing ionisation efficiencies
 
(Wang et al., 2007). 198 
Therefore, sample matrix spikes were routinely prepared and analysed with all sample 199 
batches to provide an indication of the presence of interferences which cause signal 200 
suppression/enhancement and could impact quantification. In this study, acceptable 201 
matrix recovery was considered to be 70% to 120% in accordance with previously 202 
published methods (Boix et al., 2015; USEPA, 2016; Furlong et al., 2014). Matrix 203 
‘recovery’ falling outside this range indicates signal suppression/enhancement could be 204 
occurring and samples should quantitatively be interpreted with caution. At least three 205 
matrix spike samples from different sampling sites were prepared per analytical batch to 206 
monitor for matrix effects throughout the sampling campaign as the sample matrices are 207 
heterogenous and likely to vary temporally. Surface-water matrix spikes were prepared 208 
by spiking 20 µL of 80 ng/L or 200 ng/L calibration solution into a sample replicate with 5 209 
µL of IS solution. The much higher ambient concentration of pharmaceuticals in WWTP 210 
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influent and effluent required the matrix spike samples to be prepared at a higher 211 
concentration, 4000 ng/L. Matrix recovery was calculated by subtracting the ambient 212 
sample concentration and dividing by the concentration spiked.  213 
With each sample batch at least three calibration check samples (CCSs) were 214 
prepared to monitor accuracy throughout the analytical batch (injected every 10 215 
samples). These CCSs were prepared to a concentration of 80 ng/L by pipetting 20 µL 216 
of the relevant calibration solution into 975 µL of HPLC grade water and spiked with 5 µL 217 
of IS solution. At the end of each batch a 4 ng/L calibration solution spike, prepared 218 
similarly, was also injected. The accuracy of these CCSs was required to be within 20% 219 
or affected samples were re-analysed (Furlong et al., 2014; USEPA, 2016). 220 
This formed part of a rigorous quality control plan which was followed during 221 
environmental sample analysis using a series of sample matrix  spikes, calibration 222 
solution spikes, field blanks, and laboratory blanks randomly dispersed throughout 223 
analytical batches. Further detail of quality control, how these samples were prepared 224 
and results are reported in the Supplementary Material.  225 
2.3 Analytical method validation 226 
Method validation included an assessment of precision (inter- and intra-day), limits 227 
of detection, limits of quantification, and recovery from all studied matrices. The methods 228 
and results with which each of these parameters were assessed are reported in the 229 
Supplemental Material. 230 
2.4 WWTP removal efficiency 231 
Due to access restrictions, 24 h composite samples for influent and effluent could 232 
only be collected once from WWTP A and B during summer 2016 (Supplementary 233 
Material, Table S2). Only grab samples unsuitable for estimating removals could be 234 
collected from WWTP C. WWTP removal efficiency was estimated, when appropriate, 235 
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for WWTP A and B based on mean influent and effluent concentrations according to 236 
Equation 1. In this context ‘removal’ is the change in concentration between influent and 237 
effluent which does not represent true removal, but rather partitioning to the solid phase 238 
and/or the formation of transformation products. Negative removals can occur, 239 
potentially due to sampling limitations (e.g. longer than 24 h hydraulic/sludge retention 240 
time) (Ort et al., 2010), from the conversion of conjugated metabolites back to the parent 241 
compound during treatment (Verlicchi et al. 2012), or desorption from sludge during 242 
secondary treament (Blair et al., 2015).  243 
% Removal= 1- EffluentInfluent x 100                                           [1] 244 
2.5 Statistical Analysis 245 
Data analysis was performed using Graphpad Prism (Graphpad Software, 2017). 246 
To use statistical tests when non-detects were present, data substitution according to 247 
Equation 2 was undertaken. This approach was suggested to be appropriate for left 248 
censoring of up to 40% of a dataset (Antweiler, 2015). If the non-detect frequency for a 249 
compound was greater than 40%, it was not included in statistical testing. To determine 250 
whether significant spatial differences existed between sites, pairwise t-tests were 251 
conducted based on the monthly concentrations (Furlong et al., 2017). To determine 252 
whether any analytes were seasonally variable in each river, concentrations from sites 253 
F3-F4 and O3-O4 were grouped by season and a Friedman’s Test followed by a Dunn’s 254 
multiple comparisons post hoc test was undertaken. These sites were used in the 255 
seasonality test due to their downstream location in relation to WWTP A and B, as well 256 
as their location in relation to Environment Agency flow gauges (Figure 1) as the flow 257 
recorded at these gauges was not representative of flow conditions at the remaining 258 
study sites (Center for Ecology & Hydrology, 2016). 259 
Substitution = √ *LOD                                                            [2] 260 
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2.6 Predicted environmental concentrations 261 
Annual average MECs were compared to PECs to gauge the accuracy of simple 262 
exposure algorithms commonly used for the prioritisation of pharmaceuticals and risk 263 
assessment (Burns et al., 2017). Local annual pharmaceutical usage data were obtained 264 
from the National Health Service Business Authority (National Health Service, 2016), 265 
while wastewater generation was assumed to be 200 L/person·day (European 266 
Medicines Agency, 2006). Experimental WWTP removal rates (Eqn. 1) were used with 267 
river specific dilution factors based on the average flow from sampling days to generate 268 
a PEC for both rivers. PEC calculations were based on the approach suggested by the 269 
European Medicines Agency (2006). Parameters and equations used to predict the 270 
PECs are provided in the Supplemental Material Table S6.  271 
3.0 Results & Discussion 272 
3.1 Method performance and quality control  273 
The method was determined to be sufficiently reproducible as assessed by the relative 274 
standard deviation of multiple injections (n=8) during (5.5 %RSD) and across (7.5 275 
%RSD) analysis days according to USEPA (2016) guidelines and Boix et al. (2015) 276 
where an RSD≤ 20% above the LOQ (i.e. 80 ng/L) is desirable. The limits of detections 277 
(LOD) ranged from 0.9 ng/L (carbamazepine) to 12.4 (gabapentin) and an LOD <10 ng/L 278 
was achieved for 91% of analytes (Table S5). There were no quantifiable concentrations 279 
of any of the target pharmaceuticals in field blanks collected routinely throughout the 280 
monitoring campaign. Routine matrix spikes in surface water fell within the acceptable 281 
70 – 120% recovery range for concentrations of 80 and 200 ng/L, indicating that 282 
throughout the sample analysis quantification was not unacceptably impaired due to 283 
matrix effects (Figure 2). Matrix effects were observed in WWTP effluent and influent, a 284 
phenomenon also reported by others, and suggested to be due to the presence of a 285 
greater proportion of chemical species that can affect consistent ionisation in 286 
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comparison to surface water (Boix et al., 2015; Oliveira et al., 2015). In effluent 13% and 287 
in influent 19% of analytes fell outside the acceptable matrix signal response, identified 288 
in Figure 2 and 3. Signal enhancement was most prominent for diphenhydramine in both 289 
influent and effluent (442% and 375%, respectively), while metformin (214%) and 290 
tramadol (156%) also exhibited significant signal enhancement in influent. In this study, 291 
a slight shift in relative tR of the analyte with respect to its ILIS, was observed in WWTP 292 
influent and effluent in comparison to surface water, which, in addition to it containing a 293 
larger number of chemical constituents, could help explain why matrix effects were not 294 
well compensated for all analytes using isotopically labelled internal standards. WWTP 295 
influent and effluent matrix spikes indicate that caution is needed when interpreting 296 
quantitative results and removal efficiencies due to significant matrix effects, while matrix 297 
spikes in surface water indicate that matrix effects are sufficiently compensated for by 298 
the internal standards.  299 
3.2 Pharmaceuticals in WWTPs 300 
The highest summed pharmaceutical concentrations in influent were observed in 301 
samples from WWTP B, while highest summed concentrations in effluent were observed 302 
in samples taken at WWTP A. Paracetamol had the highest concentration in all WWTP 303 
influents, 282, 186 and 117 µg/L at WWTP B, A and C, respectively. In effluent, 304 
gabapentin had the highest concentration (8541 ng/L) at WWTP C followed by 305 
metformin (6111 ng/L) at WWTP A and fexofenadine (2094 ng/L) in effluent at WWTP C. 306 
Seven pharmaceuticals (diphenhydramine, norethisterone, oseltamivir, raloxifene, 307 
sertraline, triamterene and verapamil) were not detected in any WWTP sample. Average 308 
concentration and standard deviation (SD) of WWTP influent and effluent samples are 309 
reported in the Supplemental Data Table S10. 310 
In a global review of pharmaceuticals in WWTPs, Verlicchi et al. (2012) reported 311 
influent concentrations for many compounds also observed in the WWTP samples in this 312 
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study. Codeine, paracetamol, gabapentin, hydrocodone, tramadol, erythromycin, 313 
trimethoprim, diltiazem, atenolol, propranolol, carbamazepine, gabapentin, cimetidine, 314 
and ranitidine influent concentrations all fell within the ranges reported by Verlicchi et al. 315 
(2012), while concentrations of amitriptyline were an order of magnitude lower. A study 316 
of effluents in the European Union (EU) reported average concentrations an order of 317 
magnitude lower than those determined here for tramadol, codeine, citalopram, 318 
fexofenadine, diltiazem, ranitidine, and amitriptyline, while effluent concentrations were 319 
similar for venlafaxine, trimethoprim, carbamazepine, and sulfamethoxazole in the York 320 
samples (Loos et al., 2013).  321 
The estimated removal efficiency in each WWTP is presented for all detected 322 
analytes in Figure 3. The median removal efficiency was estimated to be 75% in WWTP 323 
A and 38% in WWTP B. Paracetamol was the analyte most efficiently removed at both 324 
treatment plants (>99%), while removals greater than 75% were reported for gabapentin, 325 
ranitidine, atenolol, sulfamethoxazole, metformin, and codeine. Despite being a trickling 326 
filter plant which might be expected to have poorer pharmaceutical removal than CAS 327 
systems (Kasprzyk-Hordern et al., 2009), WWTP A had similar and even greater 328 
removals for select compounds (i.e. carbamazepine, diltiazem, citalopram, erythromycin, 329 
cimetidine, and ranitidine). In the UK specifically, similar removals were reported 330 
previously (Kasprzyk-Hordern et al., 2009) for trimethoprim, amitriptyline, diltiazem, 331 
cimetidine, gabapentin, and paracetamol, while sulfamethoxazole, erythromycin, 332 
codeine, tramadol, carbamazepine, propranolol and ranitidine were, in general, more 333 
efficiently removed for this study. WWTPs with similar treatment capabilities were also 334 
studied previously in the UK (Kasprzyk-Hordern et al., 2009). In comparison with results 335 
reported here, WWTP removal rates were highly variable despite operating in the same 336 
region and employing similar treatments, a conclusion also observed in other regions 337 
(Verlicchi et al., 2012). The single sampling event in the WWTPs is limited, however 338 
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these estimates are still useful for comparative purposes. For example, sitagliptin 339 
removal efficiency (25 - 40%) has not been previously reported to the authors’ 340 
knowledge. Therefore, while WWTPs are significant sources of pharmaceuticals entering 341 
the environment, analysis of WWTP removal efficiencies (i.e. reduction in parent 342 
pharmaceutical concentration from influent to effluent) as documented in this and 343 
previously published studies, demonstrate that WWTPs are generally decreasing the 344 
aquatic environmental burden by significantly reducing certain parent pharmaceutical 345 
concentrations (not considering degradates or transformation products) for many of the 346 
compounds studied. 347 
3.3 Pharmaceuticals in Surface Water 348 
Of the 33 pharmaceuticals monitored, 21 were detected in all 12 months in 349 
samples from the River Foss. Three compounds, oxazepam, verapamil, and triamterene, 350 
were not detected in any Foss sample. The remaining nine study compounds, 351 
diazepam, diphenhydramine, loratadine, norethisterone, oseltamivir, raloxifene, 352 
sulfamethoxazole, sertraline, and temazepam, were sporadically detected from month to 353 
month in this river. In comparison, ten compounds (carbamazepine, codeine, 354 
fexofenadine, gabapentin, hydrocodone, lidocaine, metformin, paracetamol, tramadol, 355 
and trimethoprim) were detected in all 12 months in the River Ouse samples. Eight 356 
compounds were not detected in any Ouse sample: diazepam, loratadine, oseltamivir, 357 
oxazepam, raloxifene, sulfamethoxazole, triamterene, and verapamil. The highest five 358 
annual median concentrations followed the same trend in both rivers: 359 
metformin>gabapentin>paracetamol>fexofenadine>tramadol, indicating that usage 360 
patterns, WWTP removal and environmental fate for the most prevalent pharmaceuticals 361 
are similar in these two systems. The range, detection frequency and annual median for 362 
each pharmaceutical in both river systems is reported in Tables 1 and 2. 363 
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Monthly total pharmaceutical concentrations at each sampling site are presented 364 
in Figures 4 and 5. These concentration figures provide a spatiotemporal overview of the 365 
relationship between sampling sites, rivers, and WWTPs serving the city. Monthly 366 
summed concentrations are higher in the River Foss (e.g. above 2000 ng/L) at sites 367 
downstream of the WWTP in comparison to the River Ouse, where most monthly 368 
summed concentrations are below 1000 ng/L despite the WWTPs on the River Ouse 369 
serving a larger population. This is due to greater dilution of discharged effluent in the 370 
Ouse; for example, flow ranged from 9.2 to 233 m3/s in the Ouse, compared with 0.0096 371 
to 1.68 m3/s in the Foss on sampling days (Figure 1). For the sites immediately 372 
downstream of the WWTPs (O3, O6, and F2), the months with the lowest flows, July and 373 
June, yielded both the most analytes and the highest concentrations. Thus, 374 
concentrations appear to be inversely proportional to flow at site F2, similarly to 375 
observations reported previously (Kolpin et al., 2004). The trend is not continued moving 376 
downstream in the River Foss (sites F3-F5), potentially due to pharmaceutical losses 377 
stemming from dilution or in-stream removal processes such as biodegradation or 378 
sorption to sediment (Moreno-González et al., 2014), or due to pharmaceutical 379 
contributions from domestic septic systems (Carmona et al., 2014), and/or inputs from 380 
combined sewer overflows (CSO) (Phillips et al., 2012). In the Foss, a substantial spike 381 
downstream of F2 in paracetamol (9822 ng/L) was detected in the March sampling along 382 
with less intense spikes from other pharmaceuticals, such as metformin (2592 ng/L). 383 
These observations may be explained by local septic tank effluent entering the river 384 
downstream of the F2 site, captured during the March sampling period. Paracetamol can 385 
be >99% removed and metformin >93%, in conventional water treatment (Figure 3), 386 
therefore the spike in March concentrations might be explained by releases of septic 387 
effluent (James et al., 2016). James et al. (2012) reported paracetamol concentrations of 388 
5000 ng/L at a septic effluent impacted site and identified it as a possible tracer of septic 389 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
16 
 
system contamination. Combined sewer overflow (CSO) releases could provide an 390 
alternative explanation for the concentration spike (Philips et al. 2012), as a CSO is 391 
located just upstream of the F3 site. Low rainfall (University of York, 2018) prior to 392 
sampling suggest CSOs would not likely be in operation, therefore septic effluent 393 
releases provide a plausible explanation. Concentrations in the River Ouse varied less 394 
month to month than in the Foss, and a relationship with flow was less clear, with March 395 
and May in general having slightly greater total concentrations. March has also been 396 
reported to have the highest monthly concentration in recent temporal studies (Padhye 397 
et al., 2014; Sun et al., 2014). Sun et al. (2014) suggested March coincided with a spike 398 
in pharmaceutical usage and reduced WWTP removal capacity. This may explain the 399 
slightly higher concentrations observed in the River Ouse at sites upstream of the Foss 400 
confluence (O1-O4), while the spike in May (River Ouse) coincides with decreased river 401 
flow (Figure 1). 402 
Metformin, a type II diabetes drug, had the highest annual median concentration 403 
(1117 and 237 ng/L in the Foss and Ouse, respectively), followed by gabapentin (anti-404 
convulsant) (843 and 230 ng/L, Foss and Ouse, respectively) and paracetamol 405 
(analgesic) (209 and 77.6 ng/L, Foss and Ouse, respectively). This trend is different from 406 
those observed in previous temporal exposure campaigns studying similar compounds 407 
throughout the world. For example in China, Zhang et al. (2015) studied urbanized rivers 408 
and found antibiotics the most frequently detected pharmaceuticals. They did, however, 409 
report atenolol as having one of the highest annual median concentrations (53 ng/L), 410 
which is similar to the median concentration for this compound reported at site F2 (55.4 411 
ng/L) in the current study. In Spain, Camacho-Munoz et al. (2010) reported propranolol 412 
most frequently detected in surface water, with a higher average concentration (80 ng/L) 413 
than observed in this study (20.1 ng/L). In Portugal, Paíga et al. (2016) reported 414 
carbamazepine the most frequently detected pharmaceutical with an annual median of 415 
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31.7 ng/L, while other similarly studied compounds, citalopram and venlafaxine had 416 
annual median concentrations of 0.86 and 40.1 ng/L, respectively and trimethoprim was 417 
not detected. In the River Foss, the highest annual median concentrations for 418 
carbamazepine, citalopram and venlafaxine was 66 ng/L, 15.4 and 21 ng/L, respectively 419 
while trimethoprim was detected in 100% of samples with an annual median of 30 ng/L. 420 
In Sweden, carbamazepine was also most frequently detected and at a higher annual 421 
mean than observed in York, 204 ng/L versus 66 ng/L in the River Foss, while atenolol 422 
concentration was similar to that reported here (60.2 ng/L, compared to 55.4 ng/L) 423 
(Daneshvar et al., 2010). In a similar temporal study in Wales, tramadol and gabapentin 424 
had the highest annual median concentrations (968 ng/L and 227 ng/L, respectively) 425 
(Kasprzyk-Hordern et al., 2008). Median concentrations of: gabapentin, tramadol, 426 
trimethoprim, paracetamol, carbamazepine, cimetidine and atenolol, in Wales were 427 
higher than we saw in York, while concentrations of diltiazem, atenolol, 428 
sulfamethoxazole, and erythromycin concentrations in the River Foss were lower than 429 
observed in Wales (Kasprzyk-Hordern et al., 2008). These comparisons suggest that 430 
annual pharmaceutical exposures in river systems are highly variable regionally, in part 431 
due to variability in prescribing practices, hydrology, wastewater management, and the 432 
degree of urbanisation. In addition, certain annual median concentrations of 433 
pharmaceuticals observed in this study are higher than those previously observed in the 434 
European Union and Asia. 435 
3.3.1 Spatial Trends 436 
The spatial trends for both rivers are presented in Figure 6; significant differences 437 
between a site and the adjacent downstream site are also noted. Spatial trends are 438 
apparent in both rivers, the greatest number of significant differences (p<0.05) were 439 
found between the sites upstream and downstream of the WWTPs (i.e. F1-F2, O3-O4 440 
and O5-O6) (Figure 6). In addition, significance increases were found when comparing 441 
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to sites further downstream. WWTPs make a significant contribution to pharmaceutical 442 
concentrations in both river systems, however upstream sources of certain 443 
pharmaceuticals exist in both rivers as significance was not achieved for cimetidine in 444 
the Foss and paracetamol, codeine, trimethoprim, and atenolol in the Ouse. There are 445 
WWTPs along the River Nidd (Figure 5) and upstream of sites O1 and F1 (>10 km) 446 
demonstrating that pharmaceuticals from upstream sources are transported into the city. 447 
Concentrations are generally highest immediately downstream of the WWTPs and 448 
decrease moving to downstream sites, evidenced by difference in height (i.e. 449 
concentration) between the bars from each site (Figure 6), similarly to observations in 450 
previous studies (Kasprzyk-Hordern et al., 2008). The decrease in concentrations 451 
moving downstream is variable between compounds indicating that in-stream 452 
attenuation is compound specific. For example, carbamazepine concentrations are 453 
similar between sites downstream of the WWTP in the River Foss (i.e. F2-F5), while 454 
over the same stretch of river concentrations of hydrocodone and citalopram decreases 455 
by 51% and 38%, respectively (Figure 6). In the Ouse, all concentrations decrease 456 
slightly from O3 to O4, however there is a slight increase occurring at O5, likely due to 457 
the confluence with the River Foss and again at O6, which is downstream of WWTP C. 458 
In the River Foss, carbamazepine had only a single significant spatial difference 459 
between the site upstream of WWTP A discharge (site F1) and the sites downstream of 460 
the discharge. Carbamazepine has been reported to be resistant to biodegradation and 461 
stable in the environment (Moreno-González et al., 2014). In the River Ouse, all 462 
pharmaceuticals exhibited spatially significant trends. Carbamazepine was significantly 463 
different between each site downstream of WWTP B tested (i.e. O3 to O6). Since this 464 
did not occur in the River Foss over a similar distance, 13.3 km between sites F2 and F5 465 
versus 11 km between sites O3 and O6, and the literature agrees that carbamazepine is 466 
resistant to biotransformation, a combination of dilution (e.g. urban drainage/runoff) and 467 
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other pharmaceutical sources (i.e. River Foss) moving downstream could be a plausible 468 
explanation.  469 
Overall, these results indicate that a wide variety of environmental processes such 470 
as dilution and in-stream degradation are operating to differing extents in neighbouring 471 
rivers leading to different spatial patterns in pharmaceutical concentrations between 472 
sampling sites. For example, the reduction in concentrations moving downstream in the 473 
River Foss may be symptomatic of in-stream removal processes such as photolysis or 474 
microbial degradation (Daneshvar et al., 2010), while fluctuating concentrations in the 475 
River Ouse could be due to a complex dynamic between dilution and other 476 
pharmaceutical sources (i.e. tributaries, urban drainage) while natural removal 477 
processes potentially operating in the Foss may be masked or occur to a lesser extent in 478 
the larger Ouse system. 479 
3.3.2 Seasonal Variability 480 
Temporal variability between the seasons (Figure 7) is presented similarly to the 481 
approach for displaying spatial variability between sampling sites (Figure 6). Seasonal 482 
differences in pharmaceutical concentrations exist in the two river systems, especially in 483 
the River Foss. In both rivers, the lowest concentrations correspond with winter, the 484 
season which had the highest average flow (2.7 times higher than the next highest 485 
season, autumn). Conversely, the highest mass loads occur in winter, 1.4 times higher 486 
than the next highest season, spring. Lower concentrations in winter have also been 487 
reported previously (Baker and Kasprzyk-Hordern, 2013; Kasprzyk-Hordern et al., 2008), 488 
however several studies report higher concentrations in winter (Kot-Wasik et al., 2016; 489 
Lindholm-Lehto et al., 2016; Zhang et al., 2015). In addition, the extent of concentration 490 
variability between seasons differs between compounds, which could be due to 491 
seasonal patterns in usage (Sun et al., 2014) or seasonal variability in photodegradation 492 
or biodegradation, of which both processes can peak in summer, thus having a greater 493 
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impact on more readily biodegradable compounds (Lindholm-Lehto et al., 2016). In 494 
general, autumn was the season with the second highest median concentrations, except 495 
for paracetamol, where highest median values were observed during spring in both 496 
rivers. This could be due to increased usage coinciding with symptomatic treatment of 497 
illnesses more common in spring such as colds (Vatovec et al., 2016) in conjunction with 498 
lower flows than winter. To determine whether concentrations between seasons were 499 
significant, Friedman’s test was used for pharmaceuticals with sufficient detections. 500 
Concentrations of 17 compounds (86%) were found to vary significantly by season in the 501 
River Foss, while amitriptyline, codeine, cimetidine, metformin, and ranitidine did not 502 
vary seasonally. Nine compounds (50%) had significant seasonal differences in the 503 
River Ouse, atenolol, carbamazepine, codeine, desvenlafaxine, gabapentin, lidocaine, 504 
ranitidine, sitagliptin, and trimethoprim. 505 
The reasons for temporal variations in pharmaceutical concentrations have varied 506 
between studies with several reporting flow as the major driver, observing higher 507 
concentrations during times of low flow (Kasprzyk-Hordern et al., 2008; Kolpin et al., 508 
2004). Others suggest higher pharmaceutical concentrations in winter months coincide 509 
with higher winter usage patterns (Sun et al., 2014) or decreased biodegradation in 510 
winter (Moreno-González et al., 2014), while others found no significant differences 511 
between sampled seasons (Camacho-Munoz et al., 2010). Due to higher concentrations 512 
coinciding with low-flow months in this study, we also suggest that flow appears to be a 513 
major driver behind the observed seasonal variability in pharmaceutical concentrations 514 
in the current study. The lack of significant seasonal differences found in the River Ouse 515 
could be explained by a lower annual variability in flow on sampling days than the River 516 
Foss (i.e. two orders of magnitude versus three). Further detailed investigation into the 517 
drivers behind the pharmaceutical concentrations observed both temporally and spatially 518 
is required to differentiate between the possible explanations, and could include 519 
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comparing results with prescription data and flow and estimating the impact of in-stream 520 
losses seasonally in different climates, and in river hydrological properties (e.g. depth 521 
and flow). Such analyses will be facilitated by the detailed pharmaceutical monitoring 522 
data reported in this study. 523 
 524 
3.4 Comparisons of PECs and MECs 525 
The PEC/MEC ratios for each compound for which it was possible to calculate an 526 
annual average MEC are reported in Figure 8. A ratio greater than 1 indicates PECs 527 
were higher than MECs and lower when less than 1. The PECs are severely 528 
underestimated in the Ouse; this may be due to pharmaceuticals being transported from 529 
upstream or problems with sewer connectivity within the sampling network not being 530 
accounted for in the simplistic PEC calculation. Several studies have attempted to gauge 531 
the accuracy of PECs by calculating a ratio with MECs, however the criterion for what 532 
constitutes accurate is variable across studies (Burns et al., 2017). This assessment has 533 
been previously limited to a small number of compounds and based on a limited number 534 
of sampling events not representative of the annual average MEC which the PEC was 535 
designed to predict. In this way, we present novel findings that indicate when an annual 536 
average MECs is calculated, less hydrologically complex river systems where 537 
pharmaceutical sources are limited, PECs characterise annual exposure within a factor 2 538 
for 41% of compounds in this study (average factor 2.8), with no factor greater than 11. 539 
However paracetamol is an exception (underestimated by a factor of 73); the usage 540 
estimate did not incorporate over-the-counter contributions therefore underestimates 541 
were not unexpected (Burns et al., 2017). Conversely, the results from the River Ouse 542 
indicate that major limitations are associated with this predictive approach. All ratios 543 
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were off by a factor of at least 7 (average 27) and up to 139, which according to studies 544 
characterising the PEC/MEC, is outside an acceptable range (Verlicchi et al., 2014).  545 
As the simple exposure model is routinely used for regulatory environmental risk 546 
assessment (ERA) of new pharmaceuticals, our findings have important regulatory 547 
implications. The predictions of exposure, currently being used to assess new 548 
compounds, are likely under- or over-estimating concentrations, depending on the type 549 
of compound. The use of a spatially referenced ‘down the drain’ hydrological model such 550 
as LF2000-WQX (Williams et al., 2012) or GREAT-ER (Feijtel et al., 1997) would likely 551 
result in improved predictions, as these models have the capacity to incorporate inputs 552 
from upstream sources; this is appropriate, as many rivers in the region pass through 553 
multiple urbanised areas and thus are subject to multiple WWTP inputs. In addition, the 554 
hydrological aspect can incorporate contributions or dilutions from the confluence with 555 
other river systems. Work currently being performed in the iPiE project involves the 556 
development of a spatially resolved model for European surface waters. The high-quality 557 
monitoring data presented in this study will be used to help evaluate this model. Our 558 
work also shows that inputs from other sources, potentially septic effluent, can be very 559 
important for some compounds at certain time of year. The consideration of these direct 560 
inputs in the risk assessment process may therefore be warranted. 561 
4.0 Conclusion 562 
A rapid determination HPLC-MS/MS method for 33 pharmaceuticals was validated 563 
and applied in a 12-month spatiotemporal pharmaceutical exposure campaign. WWTP 564 
removal efficiency was found to be similar between CAS and trickling filter technology for 565 
the target pharmaceuticals. Pharmaceutical concentrations in two contrasting river 566 
systems that run through the city of York, UK were found to vary significantly spatially 567 
and temporally, with the greatest variation observed for paracetamol in the River Foss, 568 
ranging from not detected to over 9822 ng/L. Temporal variations in concentration were 569 
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less frequently observed in the larger River Ouse, potentially due to the lower variability 570 
in flow which could be an important driver behind pharmaceutical concentrations in the 571 
study system. PEC/MEC ratios indicated that compounds in both rivers were generally 572 
underestimated by commonly used simple predictive exposure algorithms. In total, 41% 573 
of PEC/MEC ratios for the River Foss data were within a factor of 2, while for the River 574 
Ouse average ratios indicated predictions were off by a factor of 27. This analytical 575 
method and extensive monitoring results will be instrumental in improving the 576 
understanding of temporal pharmaceutical fate and occurrence in river systems.  577 
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Table 1. Summary results (ng/L) for the River Foss from the January to December 2016 monitoring campaign. The annual median, 
concentration range and frequency of detection for each sampling site are reported.  
Compound F1  F2  F3  F4  F5 Range (Med) %  Range (Med) %  Range (Med) %  Range (Med) %  Range (Med) % 
Amitriptyline n.d. 0  n.d. – 25.7 (10.3) 92  
1.2* – 12.2 
(5.7) 100  
n.d. – 11.2 
(2.6) 83  
n.d. – 6.4 
(2.0*) 75 
Atenolol n.d. 0  18.9 – 100 (55.4) 100  
12.3* – 98.2 
(43.6) 100  
13.7* – 97.8 
(34.8) 100  
10.1* – 67.0 
(21.8) 100 
Carbamazepine n.d. – 11.8 (4.5) 67  
19.0 –195 
(45.2) 100  
8.7 – 194 
(66.0) 100  
12.5 – 175 
(61.6) 100  
11.4 – 193 
(36.8) 100 
Cimetidine n.d. – 49.6 (19.8) 83  
n.d. – 44.0 
(19.9) 92  
3.0* - 40.5 
(10.6) 100  
2.1* - 16.9 
(7.3*) 100  
n.d. – 11.8 
(7.2*) 67 
Citalopram n.d. 0  5.0 – 71.4 (15.4) 100  
3.8* - 31.0 
(15.3) 100  
3.1* - 13.5 
(7.8) 100  
n.d. – 11.4 
(5.9) 83 
Codeine n.d. – 10.8 (5.9*) 83  
8.0 – 101 
(59.2) 100  
11.5 – 84.2 
(57.3) 100  
12.9 – 97.7 
(44.0) 100  
12.0 – 64.7 
(29.1) 100 
Desvenlafaxine n.d. – 55.8 (16.8) 83  
25.8 – 268 
(70.0) 100  
4.6* - 195 
(86.2) 100  
11.7 – 170 
(77.3) 100  
8.5* - 96.4 
(44.5) 100 
Diazepam n.d. 0  n.d. – 1.6* (n.d.) 8.3  
n.d. - 1.6* 
(n.d.) 8.3  
n.d. - 1.8* 
(n.d.) 8.3  
n.d. - 2.3* 
(n.d.) 8.3 
Diltiazem n.d. – 4.1 (1.2*) 75  
4.7 – 48.7 
(16.4) 100  
4.7 – 36.0 
(14.5) 100  
4.4 – 25.0 
(10.6) 100  
n.d. – 12.7 
(5.8) 92 
Diphenhydramine n.d. 0  n.d. -12.7 (9.5) 67  
n.d. – 3.8 
(n.d.) 25  
n.d. – 1.6* 
(n.d.) 17  
n.d. – 3.4 
(n.d.) 8.3 
Erythromycin n.d. – 34.5 (20.2*) 58  
26.8 – 242 
(90.0) 100  
15.0* - 263 
(88.8) 100  
18.8* - 142 
(80.5) 100  
14.4 – 116 
(45.9) 100 
Fexofenadine1 n.d. – 104 (24.9) 83  
43.8 – 1144 
(177) 100  
17.2 – 956 
(253) 100  
27.5 – 638 
(166) 100  
26.4 – 268 
(92.5) 100 
Gabapentin 17.4* – 229 (82.7) 100  
476 – 1429 
(789) 100  
260 – 1445 
(843) 100  
404 – 1183 
(768) 100  
223 – 1341 
(544) 100 
Hydrocodone n.d. – 5.7  (n.d.) 43  
11.2 – 91.8 
(21.6) 100  
6.4 – 60.3 
(25.0) 100  
6.8 – 43.5 
(20.6) 100  
5.2 – 22.2 
(11.1) 100 
Lidocaine n.d. – 3.9 (2.6*) 58  
4.6 – 40.4 
(8.2) 100  
1.7* - 39.7 
(11.8) 100  
3.1 – 36.9 
(10.4) 100  
n.d. – 16.0 
(6.1) 92 
Loratadine n.d. 0  n.d. 0  n.d. – 6.46 (n.d.) 8.3  n.d. 0  n.d. 0 
Metformin 45.2 – 291 (121) 100  
246 -1783 
(856) 100  
266 – 2339 
(1117) 100  
340 – 2595 
(888) 100  
263 – 1750 
(664) 100 
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Table 1. Summary results for the River Foss from the January to December 2016 monitoring campaign. The annual median, concentration 
range and frequency of detection for each sampling site are reported.  
Compound F1  F2  F3  F4  F5 Range (Med) %  Range (Med) %  Range (Med) %  Range (Med) %  Range (Med) % 
Norethisterone n.d. 0  n.d. – 7.4* (n.d.) 8.3  n.d. 0  n.d. 0  n.d. 0 
Oseltamivir n.d. 0  n.d. – 8.8* (n.d) 8.3  n.d. 0  n.d. 0  n.d. 0 
Oxazepam n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Paracetamol n.d. – 119 (60.0) 67  
14.3* - 749 
(74.4) 100  
n.d. – 9822 
(97.2) 92  
32.0 – 9676 
(209) 100  
25.0 – 5445 
(180) 100 
Propranolol n.d. 0  n.d. – 64.9 (17.8) 92  
n.d. – 29.9 
(20.1) 92  
n.d. – 20.6 
(10.0*) 92  
n.d. – 18.3 
(10.4*) 50 
Raloxifene n.d. 0  n.d. 0  n.d. -7.2* 8.3   n.d. – 7.2* 8.3  n.d. 0 
Ranitidine n.d. – 10.8* (n.d.) 17  
n.d. – 69.6 
(53.4) 83  
6.6* – 74.0 
(27.9) 100  
n.d. – 60.6 
(22.2) 92  
n.d. – 30.0 
(13.6*) 92 
Sertraline n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. - 21.2 (n.d) 8.3 
Sitagliptin n.d. 0  16.5 – 121 (35.2) 100  
9.3* - 103 
(46.5) 100  
15.2 – 85.7 
(36.9) 100  
12.2* – 33.9 
(19.5) 100 
Sulfamethoxazole n.d. 0  n.d. – 10.2* (n.d.) 33  
n.d. – 33.0 
(n.d.) 50  
n.d. – 27.5 
(n.d. 42  
n.d. – 18.1* 
(n.d.) 17 
Temazepam n.d. 0  n.d. – 38.2 (12.1) 67  
n.d. – 25.0 
(16.7) 75  
n.d. – 27.8 
(15.9) 67  
n.d. – 12.6 
(7.1*) 58 
Tramadol n.d. – 48.1 (31.2) 75  
54.4 – 650 
(117) 100  
21.0 – 456 
(177) 100  
34.0 – 368 
(169) 100  
29.2 – 201 
(84.7) 100 
Triamterene n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Trimethoprim n.d. – 9.8 
 (2.5*) 75  
13.2 - 76.0 
(30.3) 100  
10.1- 60.3 
(26.4) 100  
15.2 – 49.4 
(19.8) 100  
5.3 – 38.0 
(13.8) 100 
Venlafaxine n.d. – 4.3 (2.2*) 42  
9.2 – 102 
(16.2) 100  
2.4* – 82.6 
(20.6) 100  
5.9 – 37.9 
(17.6) 100  
2.3* -17.8  
(9.2) 100 
Verapamil n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
*Below LOQ 
1 data for 11 months only available (April 2016 missing). 
n.d. No detect 
(Med) Median 
% Detection frequency (100% = 12 months) 
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Table 2. Summary results (ng/L) for the River Ouse from the January to December 2016 monitoring campaign. The annual median, concentration range and 
frequency detection for each sampling site are reported. 
Compound 
O1  O2  O3  O4  O5  O6 
Range 
(med) % 
 Range 
(med) % 
 Range 
(med) % 
 Range 
(med) % 
 Range 
(med) % 
 Range 
(med) % 
Amitriptyline n.d. 0  n.d. 0  n.d. – 2.7 (n.d.) 17 
 n.d. -1.2* 
(n.d.) 17 
 n.d. – 1.5* 
(n.d.) 8 
 n.d. -2.5 
(n.d.) 17 
Atenolol n.d. 0  n.d. – 22.0 (11.1*) 58 
 n.d. – 19.5 
(10.7*) 67 
 n.d. – 16.9* 
(10.2*) 75 
 n.d. – 20.4 
(10.4*) 67 
 n.d. – 18.8 
(13.6*) 92 
Carbamazepine 1.0* – 14.0 (5.8) 100 
 1.1* - 34.8 
(9.2) 100 
 1.4* - 54.4 
(19.2) 100 
 1.1* - 31.4 
(12.1) 100 
 1.7* - 33.9 
(15.0) 100 
 7.9 – 48.0 
(23.4) 100 
Cimetidine n.d. – 2.3* (n.d.) 8 
 n.d. – 2.4* 
(n.d.) 8 
 n.d. - 5.7* 
(n.d.) 33 
 n.d. – 2.9* 
(n.d.) 17 
 
n.d. 0  n.d. – 3.7 
 (n.d.) 42 
Citalopram n.d. - 3.3*  (n.d.) 8 
 n.d. – 3.7* 
(n.d.) 33 
 n.d. – 7.0 
(4.0*) 75 
 n.d. – 3.2* 
(n.d.) 50 
 n.d. – 4.0* 
(2.2*) 67 
 n.d. – 7.2   
(4.8) 83 
Codeine n.d. – 13.5 (10.5*) 92 
 3.3 – 17.1 
(10.7)  100 
 3.0* – 20.5 
(14.3) 100 
 3.5* – 17.5 
(13.8) 100 
 4.5* – 17.4 
(14.9) 100 
 6.4* - 17.8  
(8.8) 100 
Desvenlafaxine n.d. – 14.8 (n.d.) 50 
 n.d. – 27.5 
(11.3) 75 
 n.d. – 46.8 
(21.5) 83 
 n.d. -31.0 
(14.2) 83 
 n.d. – 28.8 
(15.2) 75 
 12.3 – 40.1 
(26.8) 100 
Diazepam n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Diltiazem n.d. – 1.6* (n.d.) 25 
 n.d. – 2.5 
(n.d.) 50 
 n.d. – 8.0  
(3.6) 92 
 n.d. – 6.4 
(1.8*) 67 
 n.d. – 3.7 
(1.8*) 75 
 n.d. – 4.3  
(3.7) 92 
Diphenhydramine n.d. 0  n.d. – 1.7* (n.d.) 8 
 n.d.- 2.9 
(n.d.) 25 
 
n.d. 0  n.d.- 4.8  (n.d.) 8 
 n.d. - 2.2* 
(n.d.) 8 
Erythromycin n.d. 0  n.d. – 17.3* (n.d.) 33  
n.d. – 31.1 
(21.3*) 92  
n.d. – 20.3* 
(15.3*) 67  
n.d. – 21.7* 
(n.d.) 50  
n.d. – 33.9 
(21.3*) 83 
Fexofenadine1 n.d. – 41.7 (17.9) 83  
n.d. – 48.7 
(24.1) 83  
n.d. – 77.8 
(46.1) 92  
n.d. – 68.2 
(25.8) 83  
n.d. – 44.0 
(29.2) 92  
7.4* – 98.5 
(33.4) 100 
Gabapentin 28.1* -242 (130) 100  
39.4 – 351 
(191) 100  
24.5* - 429 
(230) 100  
30.0* - 369 
(202) 100  
33.8* - 364 
(192) 100  
39.5 – 450 
(208) 100 
Hydrocodone n.d. – 2.9 (n.d.) 50  
n.d. – 5.7 
(3.6) 83  
n.d. – 14.9 
(7.8) 92  
n.d. – 8.0 
(4.0) 92  
n.d. – 6.9 
(4.0) 92  
2.2 – 10.7 
(6.0) 100 
Lidocaine n.d. – 4.1 (n.d.) 50  
n.d. – 5.0 
(2.7*) 83  
n.d. – 6.5  
(3.7) 92  
n.d. – 5.4 
(2.8) 83  
n.d. – 5.6 
(3.1) 83  
1.6* – 8.8 
(4.1) 100 
Loratadine n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Metformin 52.5 – 323 (180) 100  
63.4 – 431 
(223) 100  
60.6 – 422 
(237) 100  
60.2 – 422 
(237) 100  
73.6 – 445 
(233) 100  
142 – 483 
(276) 100 
Norethisterone n.d. 0  n.d. -7.7 (n.d.) 8  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Oseltamivir n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
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Table 2. Summary results (ng/L) for the River Ouse from the January to December 2016 monitoring campaign. The annual median, concentration range and 
frequency detection for each sampling site are reported. 
Compound 
O1  O2  O3  O4  O5  O6 
Range 
(med) %  
Range 
(med) %  
Range 
(med) %  
Range 
(med) %  
Range 
(med) %  
Range 
(med) % 
Oxazepam n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Paracetamol 22.3* – 191 (46.4) 100  
15.4* - 202 
(51.7) 100  
16.8* – 186 
(54.5) 100  
20.1* – 186 
(54.3) 100  
22.7 – 369 
(77.6) 100  
21.2 – 226 
(66.9) 100 
Propranolol n.d. 0  n.d. 0  n.d. – 8.3* (n.d.) 33  n.d. 0  n.d. 0  
n.d. – 7.6* 
(n.d.) 8 
Raloxifene n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Ranitidine n.d. -10.3* (n.d.) 25  
n.d. – 10.5* 
(n.d.) 25  
n.d. – 30.6 
(15.1*) 75  
n.d. - 13.3* 
(n.d.) 42  
n.d. – 12.0* 
(n.d.) 25  
n.d. – 15.5* 
(9.2*) 75 
Sertraline n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Sitagliptin n.d. – 10.7 (n.d.) 33  
n.d. – 16.2 
(9.3*) 75  
n.d. – 32.5 
(15.0) 92  
n.d. – 16.9 
(12.0*) 83  
n.d. – 15.8 
(10.4*) 83  
n.d. – 26.5 
(18.2) 92 
Sulfamethoxazole n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Temazepam n.d. 0  n.d. 0  n.d. – 7.2* (n.d.) 8  n.d. 0  
n.d. – 4.4* 
(n.d.) 8  
n.d. – 4.7* 
(n.d.) 8 
Tramadol n.d. – 27.0 (19.6) 83  
3.9* - 39.9 
(19.8) 100  
n.d. – 57.2 
(34.6) 92  
n.d. – 44.8 
(28.9) 92  
n.d. – 47.4 
(27.4) 92  
20.7 – 52.4 
(40.5) 100 
Triamterene n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Tramadol n.d. – 27.0 (19.6) 
83  3.9* - 39.9 
(19.8) 
100  n.d. – 57.2 
(34.6) 
92  n.d. – 44.8 
(28.9) 
92  n.d. – 47.4 
(27.4) 
92  20.7 – 52.4 
(40.5) 
100 
Triamterene n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
Trimethoprim n.d. – 19.0 (2.7) 
92  2.0* – 8.9 
(5.3) 
100  2.8* - 19.3 
(12.4) 
100  n.d. – 11.1 
(5.4) 
92  2.3* - 12.1 
(5.5) 
100  7.3 – 22.9 
(14.2) 
100 
Venlafaxine n.d. – 2.6* (n.d.) 
42  n.d. – 5.2 
(2.6*) 
75  n.d. – 8.5* 
(4.9) 
83  n.d. – 4.3 
(2.9*) 
75  n.d. – 5.0 
(3.1) 
75  n.d. – 8.2 
(4.5) 
83 
Verapamil n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0  n.d. 0 
* Below LOQ 
1 data for 11 months only available (April 2016 missing). 
n.d. No detect 
(Med) Median 
% Detection frequency (100% = 12 months) 
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Figure 1. Map of 11 sampling sites within the sampling network.  River flows recorded from a 
gauge in each river (orange triangle) from each sampling day (m3/s) are pictured top left. 
WWTPs that serve the city (3) are represented by the red rectangles. Sites F1-F5 are along the 
smaller River Foss, while sites O1-O6 are along the larger River Ouse.
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Figure 2. A) Routine matrix spikes run alongside environmental samples during the 12-month monitoring
campaign in WWTP influent, effluent, surface water and reagent water. The dotted lines represent the 70 
120% acceptable recovery range. B) %RSD of matrix spike replicates. An RSD below 20% is desirable
(depicted with dotted line). The median, 25th and 75th quartiles are presented while the whiskers represent
the 10th to 90th percentile, compounds outside this range are depicted with an X.
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Figure 3.  Estimated % removal in WWTP A (trickling filter), WWTP B (carbon activated sludge).
Hydrocodone not shown, estimated removal in WWTP A -307% and in WWTP B -597%. Matrix
recovery was outside the 70 -120% desired range is identified for (a) influent and (b) effluent.
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Figure 4. Total pharmaceutical concentration (summed) of all detected analytes at each sampling site
from each month during 2016 in the River Foss. Sampling locations (blue circles) in relation to
Environment Agency Flow gauges (orange triangles) are depicted along the river.
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Figure 5. Total pharmaceutical concentration (summed) of all detected analytes at each sampling site from each
month during 2016 along the River Ouse. Sampling locations (blue circles) in relation to Environment Agency Flow
gauges (orange triangles) are depicted along the river.
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Figure 6. Annual median concentration from all sampled sites in (A) the River Foss and (B)
River Ouse. Pairwise t-tests were conducted between neighbouring sites and significant
differences are denoted by the corresponding number. Sites F1-F2, O1-O2 =1; F2-F3, O2-O3
=2; F3-F4, O3-O4 =3; F4-F5, O4-O5 =4; O5-O6 =5.
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Figure 7.  Median seasonal concentration from sites F3-F4 in the River Foss :;< =nd O3-O4
in the River Ouse :>< for select pharmaceuticals.  Temporal variations were tested using
Friedman's Test and results are reported for each compound where a significant result was
found, p?@A@5 (B<C p?@A@1 :BB<C p?@A@@@5 :BBB<, p?@A@@@1 (BBBB<.
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DEGHIJ K. The annual average PEC/MEC ratios are plotted for the River FoMM NoPQR STUSVQMW XRY Z[Q \T]QU
Ouse (closed STUSVQMWc PECs were calculated for each river based on experimental WWTP removals and
the average flow from sampling days. PEC/MEC ratios were calculated for site F2-F5 and O3-O6 and
averaged, error bars represent the standard deviation.
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Highlights 
• 11 sites from two nested river systems sampled monthly for one year. 
• Seasonal and spatial variation due to flow, usage and compound stability. 
• Removal efficiency estimated for 24 pharmaceuticals in two WWTPs. 
• Disagreement between measured concentrations and exposure model 
predictions. 
 
